Custom service

Enzyme Replacement Therapy ADA Testing

Measure ada against enzyme replacement therapies

Turnaround: 10–14 weeksTypical scale: µg – g sample scaleChemistry options: inhibition-of-uptake (IOU) assay design; drug-tolerant formats; cross-reactive antibody handling

Teams come to this service when they need to measure ADA against enzyme replacement therapies. We typically start from inhibition-of-uptake (IOU) assay design, add drug-tolerant formats where the application demands it, and close the loop with cross-reactive antibody handling so the final ERT ADA testing package behaves consistently across lots.

Design reviews are part of the schedule, not an extra. Sequence, spacer architecture and analytical strategy are signed off before the first synthesis run, which is why the 10–14 weeks timeline holds in practice.

Lysosomal storage disorder programs

Distinguishing inhibitory from binding ADA

Non-protein replacement therapies

Samples requiring containment or licensing we do not hold (BSL-3, radioactive)

Analytical reports follow a fixed template: sample condition on receipt, method description with validation status, raw chromatograms and spectra, results with uncertainty, and an interpretation note. Urgent same-week slots are available for release-critical testing.

Service Highlights

  • Inhibition-of-uptake (IOU) assay design as the default route, with drug-tolerant formats held as a proven fallback
  • Cross-reactive antibody handling worked into the design where the application requires it
  • Results are reported with detection limits and method validation status, so you know exactly what the number means
  • Analytical confirmation of every intermediate before the final release
  • Orthogonal methods are used by default — one measurement is an observation, two are data
  • ERT ADA testing package delivered with a complete conjugation or synthesis certificate

How the work runs

  1. Sample intake & plan

    Samples are logged with chain of custody and the test matrix for Enzyme Replacement Therapy ADA Testing is confirmed.

  2. Method selection

    Analytical methods — inhibition-of-uptake (IOU) assay design, drug-tolerant formats — are chosen and their validation status documented.

  3. Measurement

    Testing is executed with system-suitability checks and orthogonal confirmation where required.

  4. Data review

    Chromatograms and spectra are reviewed by a second analyst before any result is issued.

  5. Reporting

    ERT ADA testing package is issued with detection limits and interpretation notes.

  6. Follow-up support

    We discuss anomalies and, where useful, propose the follow-up experiment that resolves them.

Specifications & timeline

Turnaround
10–14 weeks
Typical scale
µg – g sample scale
Chemistry options
inhibition-of-uptake (IOU) assay design; drug-tolerant formats; cross-reactive antibody handling
Deliverable
ERT ADA testing package
QC package
Method report, raw data, validated result with detection limits
Shipping
Blue ice or ambient by material; chain-of-custody on receipt

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.